Cumberland Pharmaceuticals Inc.
CPIX
$4.35
-$1.01-18.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.84% | 24.49% | -9.92% | -9.55% | -7.88% |
| Total Other Revenue | -- | -34.76% | -- | -- | -- |
| Total Revenue | 37.84% | 11.57% | -9.92% | -9.55% | -7.88% |
| Cost of Revenue | -9.51% | 29.18% | -25.07% | 12.50% | 26.01% |
| Gross Profit | 48.61% | 8.13% | -6.70% | -13.13% | -13.19% |
| SG&A Expenses | 2.64% | -7.92% | -0.20% | -0.52% | -3.75% |
| Depreciation & Amortization | -9.49% | 22.09% | -8.25% | -5.03% | -9.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.52% | 0.73% | -9.81% | 0.09% | -3.62% |
| Operating Income | 169.11% | 35.04% | 9.23% | -4,583.41% | -22.04% |
| Income Before Tax | 166.31% | 68.80% | -44.42% | -225.56% | -1,155.25% |
| Income Tax Expenses | -50.00% | -328.00% | 65.22% | 65.22% | 65.22% |
| Earnings from Continuing Operations | 165.61% | 69.83% | -44.56% | -227.88% | -1,204.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 120.32% | -128.95% | -151.08% | 70.00% | -320.10% |
| Net Income | 164.59% | 69.75% | -47.16% | -224.47% | -1,112.64% |
| EBIT | 169.11% | 35.04% | 9.23% | -4,583.41% | -22.04% |
| EBITDA | 423.34% | 78.43% | 6.78% | -90.78% | -160.36% |
| EPS Basic | 160.90% | 69.33% | -49.52% | -226.90% | -1,130.60% |
| Normalized Basic EPS | 160.99% | 31.89% | -30.63% | -222.66% | -1,044.57% |
| EPS Diluted | 157.14% | 68.51% | -49.66% | -233.33% | -1,500.00% |
| Normalized Diluted EPS | 159.72% | 31.89% | -30.63% | -223.95% | -1,065.56% |
| Average Basic Shares Outstanding | 5.99% | -1.36% | -1.57% | -1.91% | -1.82% |
| Average Diluted Shares Outstanding | 8.24% | -1.36% | -1.57% | -3.00% | -3.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |